• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    REGENXBIO Inc. - Common Stock (NQ:RGNX)

    8.055 -0.205 (-2.48%)
    Streaming Delayed Price Updated: 11:01 AM EDT, Mar 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 136,904
    Open 8.180
    Bid (Size) 8.040 (200)
    Ask (Size) 8.070 (100)
    Prev. Close 8.260
    Today's Range 7.920 - 8.350
    52wk Range 5.035 - 16.19
    Shares Outstanding 43,466,186
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
    On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)... 
    Via Finterra
    Topics Economy Initial Public Offering
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
    From Pomerantz LLP
    Via GlobeNewswire

    Performance

    YTD
    -40.6%
    -40.6%
    1 Month
    -0.3%
    -0.3%
    3 Month
    -43.1%
    -43.1%
    6 Month
    -13.9%
    -13.9%
    1 Year
    -1.8%
    -1.8%

    More News

    Read More
    News headline image
    RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action
    From Robbins LLP
    Via Business Wire
    News headline image
    RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    RGNX DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Stephen Pakola Oversaw RGX-111 Safety Claims That Cost RGNX Investors Millions: Levi & Korsinsky, LLP
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    RGNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study ↗
    Via Stocktwits
    Topics Death
    News headline image
    RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGNX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings

    Frequently Asked Questions

    Is REGENXBIO Inc. - Common Stock publicly traded?
    Yes, REGENXBIO Inc. - Common Stock is publicly traded.
    What exchange does REGENXBIO Inc. - Common Stock trade on?
    REGENXBIO Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for REGENXBIO Inc. - Common Stock?
    The ticker symbol for REGENXBIO Inc. - Common Stock is RGNX on the Nasdaq Stock Market
    What is the current price of REGENXBIO Inc. - Common Stock?
    The current price of REGENXBIO Inc. - Common Stock is 8.055
    When was REGENXBIO Inc. - Common Stock last traded?
    The last trade of REGENXBIO Inc. - Common Stock was at 03/27/26 11:01 AM ET
    What is the market capitalization of REGENXBIO Inc. - Common Stock?
    The market capitalization of REGENXBIO Inc. - Common Stock is 350.12M
    How many shares of REGENXBIO Inc. - Common Stock are outstanding?
    REGENXBIO Inc. - Common Stock has 350M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.